mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

View original at finance.yahoo.com
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Olema Oncology On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Initial clinical results from OP-3136 are anticipated in Q2 2026

    60% confidence

  • 2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens

    60% confidence

  • Commercial launch preparations are underway for a potential approval in late 2027

    60% confidence

  • Palazestrant has potential as the combination endocrine therapy of choice in the metastatic setting

    60% confidence

  • Top-line data from OPERA-01 is expected in the fall of 2026

    60% confidence

  • Transformation into a fully-integrated oncology company is underway in preparation for the Company's first potential commercial launch in late 2027

    60% confidence

  • The November 2025 public offering enables funding operations through numerous expected value-creating events with palazestrant

    60% confidence

  • Olema is on-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial

    60% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results — Source | Via News | fr.VIA.NEWS